Urcosimod Phase 2 Results to be Presented at ASCRS 2026 Annual Meeting

OKYO Pharma's lead candidate, urcosimod, has been accepted for presentation at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting. The abstract highlights efficacy and safety findings from a Phase 2 proof-of-concept study in patients with neuropathic corneal pain. Urcosimod was previously granted IND approval and fast-track designation by the FDA. OKYO plans to begin a Phase 2b/3 multiple-dose study in the first half of 2026.